Volume | 3,411,885 |
|
|||||
News | - | ||||||
Day High | 6.29 | Low High |
|||||
Day Low | 6.10 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Adma Biologics Inc | ADMA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
6.1999 | 6.10 | 6.29 | 6.27 | 6.20 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
17,283 | 3,411,885 | US$ 6.19 | US$ 21,129,717 | - | 3.06 - 6.76 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:58:48 | 5 | US$ 6.28 | USD |
Adma Biologics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.43B | 228.22M | - | 258.22M | -28.24M | -0.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Adma Biologics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADMA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.225 | 6.29 | 5.93 | 6.10 | 1,932,607 | 0.045 | 0.72% |
1 Month | 6.26 | 6.76 | 5.895 | 6.33 | 2,282,836 | 0.01 | 0.16% |
3 Months | 5.13 | 6.76 | 5.02 | 5.87 | 2,523,613 | 1.14 | 22.22% |
6 Months | 3.34 | 6.76 | 3.06 | 5.06 | 2,330,458 | 2.93 | 87.72% |
1 Year | 3.32 | 6.76 | 3.06 | 4.48 | 2,218,635 | 2.95 | 88.86% |
3 Years | 1.62 | 6.76 | 1.01 | 2.74 | 2,918,690 | 4.65 | 287.04% |
5 Years | 4.50 | 6.76 | 1.01 | 2.78 | 2,772,116 | 1.77 | 39.33% |
Adma Biologics Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. |